SCHEMBL2090980

SCHEMBL2090980

CO[CH]C(=O)Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
EPHX2 P34913 4/20 0.63
MAPT P10636 2/20 0.54
TRPV1 Q8NER1 3/20 0.54
ALDH1A1 P00352 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
HPGD P15428 1/20 0.52
KDM4E B2RXH2 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
FAAH O00519 1/20 0.50
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6002397 0.84 KMT2A (0.59) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL2098409 0.82 TGM2 (0.69) KMT2AMAPTTRPV1ALDH1A1L3MBTL1
SCHEMBL8858788 0.81 KMT2A (0.73) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL8858784 0.81 KMT2A (0.73) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL30459766 0.81 KMT2A (0.68) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL2088524 0.81 TGM2 (0.63) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL22471889 0.81 KMT2A (0.59) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL515175 0.80 EPHX2 (0.71) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL9070653 0.78 EPHX2 (0.73) KMT2AEPHX2MAPTTRPV1ALDH1A1
SCHEMBL9285859 0.78 KMT2A (0.64) KMT2AEPHX2MAPTTRPV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KMT2A 3324/4885EPHX2 3472/4885MAPT 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.